We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Eli Lilly, Accenture, TJX, Novo Nordisk and Salesforce
Read MoreHide Full Article
For Immediate Release
Chicago, IL – November 27, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Eli Lilly and Company (LLY - Free Report) , Accenture plc (ACN - Free Report) , The TJX Companies, Inc. (TJX - Free Report) , Novo Nordisk A/S (NVO - Free Report) and Salesforce, Inc. (CRM - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Stock Reports for Eli Lilly, Accenture & TJX Companies
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company, Accenture plc and The TJX Companies, Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Eli Lilly shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+64.5% vs. +11.1%). The company’s revenue growth is being driven by higher demand for drugs like Verzenio, Trulicity, Taltz and others.
Sales of its weight-loss drug, Mounjaro, are already benefiting from strong demand trends. Mounjaro is expected to be a key long-term top-line driver for Lilly as it has the potential to be approved for obesity and other diabetes-related diseases. Mounjaro showed superior weight-loss reduction in clinical studies for obesity. Lilly expects regulatory decisions for some key pipeline candidates this year.
However, generic competition for some drugs, rising pricing pressure and challenges in meeting strong demand for incretin products are some top-line headwinds. Estimates have declined slightly ahead of Q3 results. Lilly has a mixed record of earnings surprises in the recent quarters
Shares of Accenture have gained +14.2% over the past year against the Zacks Consulting Services industry’s gain of +15.8%. The company has been steadily gaining traction in its outsourcing and consulting businesses backed by high demand for services that can improve operating efficiencies and save costs.
Accenture has been strategically enhancing its cloud and digital marketing suite through buyouts and partnerships. The company’s strong operating cash flow has helped it reward its shareholders in the form of dividend payments and share repurchases, and pursue opportunities in areas that show true potential. Partly due to these tailwinds,
On the flip side, pricing pressure due to significant competition from strong companies like Genpact, Cognizant and Infosys, remains a concern. Global presence exposes it to foreign currency exchange rate fluctuations. Buyout-related integration risks continues to remain a concern.
Shares of The TJX Companies have outperformed the Zacks Retail - Discount Stores industry over the past year (+12.7% vs. -1.2%). The company’s top and bottom lines beat the Zacks Consensus Estimate in last week's second quarter of fiscal 2024 results. Its off-price business model, strategic store locations, impressive brands and fashion products and supply-chain management have been working well.
TheTJX Companies is benefiting from its solid store and e-commerce growth efforts. TJX’s Marmaxx segment is doing particularly well, where comp store sales grew in the fiscal second quarter, backed by improved customer traffic. The recovery of the HomeGoods (U.S.) division bodes well.
However, TJX has been grappling with high wage and supply-chain costs. It expects these costs to be deterrents in fiscal 2024. A high debt level poses a concern for the company. Currency might also act as a deterrent.
Other noteworthy reports we are featuring today include Novo Nordisk A/S and Salesforce, Inc.
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
The Zacks Analyst Blog Highlights Eli Lilly, Accenture, TJX, Novo Nordisk and Salesforce
For Immediate Release
Chicago, IL – November 27, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Eli Lilly and Company (LLY - Free Report) , Accenture plc (ACN - Free Report) , The TJX Companies, Inc. (TJX - Free Report) , Novo Nordisk A/S (NVO - Free Report) and Salesforce, Inc. (CRM - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Stock Reports for Eli Lilly, Accenture & TJX Companies
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company, Accenture plc and The TJX Companies, Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Eli Lilly shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+64.5% vs. +11.1%). The company’s revenue growth is being driven by higher demand for drugs like Verzenio, Trulicity, Taltz and others.
Sales of its weight-loss drug, Mounjaro, are already benefiting from strong demand trends. Mounjaro is expected to be a key long-term top-line driver for Lilly as it has the potential to be approved for obesity and other diabetes-related diseases. Mounjaro showed superior weight-loss reduction in clinical studies for obesity. Lilly expects regulatory decisions for some key pipeline candidates this year.
However, generic competition for some drugs, rising pricing pressure and challenges in meeting strong demand for incretin products are some top-line headwinds. Estimates have declined slightly ahead of Q3 results. Lilly has a mixed record of earnings surprises in the recent quarters
(You can read the full research report on Eli Lilly here >>>)
Shares of Accenture have gained +14.2% over the past year against the Zacks Consulting Services industry’s gain of +15.8%. The company has been steadily gaining traction in its outsourcing and consulting businesses backed by high demand for services that can improve operating efficiencies and save costs.
Accenture has been strategically enhancing its cloud and digital marketing suite through buyouts and partnerships. The company’s strong operating cash flow has helped it reward its shareholders in the form of dividend payments and share repurchases, and pursue opportunities in areas that show true potential. Partly due to these tailwinds,
On the flip side, pricing pressure due to significant competition from strong companies like Genpact, Cognizant and Infosys, remains a concern. Global presence exposes it to foreign currency exchange rate fluctuations. Buyout-related integration risks continues to remain a concern.
(You can read the full research report on Accenture here >>>)
Shares of The TJX Companies have outperformed the Zacks Retail - Discount Stores industry over the past year (+12.7% vs. -1.2%). The company’s top and bottom lines beat the Zacks Consensus Estimate in last week's second quarter of fiscal 2024 results. Its off-price business model, strategic store locations, impressive brands and fashion products and supply-chain management have been working well.
TheTJX Companies is benefiting from its solid store and e-commerce growth efforts. TJX’s Marmaxx segment is doing particularly well, where comp store sales grew in the fiscal second quarter, backed by improved customer traffic. The recovery of the HomeGoods (U.S.) division bodes well.
However, TJX has been grappling with high wage and supply-chain costs. It expects these costs to be deterrents in fiscal 2024. A high debt level poses a concern for the company. Currency might also act as a deterrent.
(You can read the full research report on The TJX Companies here >>>)
Other noteworthy reports we are featuring today include Novo Nordisk A/S and Salesforce, Inc.
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.